PEPTIDE GUIDE

What Is GHRP-6?

GHRP-6 is a laboratory-made peptide containing six amino-acid-like building blocks. Its full name is growth hormone-releasing peptide 6. It activates the ghrelin receptor, a signalling protein involved in growth hormone release, appetite, glucose regulation and several other body systems.

Scientists first described the sequence in the 1980s, before they knew which receptor it used and before the natural hormone ghrelin had been discovered. Human experiments later showed that GHRP-6 can prompt growth hormone release. Small studies also measured sleep, stress hormones and the way the body handles the peptide. More recently, researchers tested GHRP-6 together with epidermal growth factor after ischaemic stroke. The larger 2026 trial did not meet its main effectiveness target.

GHRP-6 is not growth hormone and is not an approved general treatment for recovery, muscle gain, fat loss, sleep or anti-ageing. Its research record is broader than online summaries sometimes suggest, but it is also less supportive of popular claims than those summaries imply.

Research statusInvestigational ghrelin-receptor agonist with limited human evidence
Development nameSKF-110679
Peptide typeSix-residue synthetic ghrelin-receptor agonist
Human evidenceLimited endocrine and combination-treatment research
Last reviewedSeptember 2026
THE SHORT ANSWER

GHRP-6 is a six-residue synthetic peptide that activates the ghrelin receptor and can produce a rapid growth hormone response. Small human studies have examined hormone release, sleep, diagnostic testing and pharmacokinetics, which means the movement of a compound through the body. GHRP-6 has also been tested with epidermal growth factor in people with acute ischaemic stroke, but the 2026 Phase III trial found no overall improvement in disability or survival in the full study population. GHRP-6 has not been shown in controlled clinical trials to build useful muscle, reduce body fat, heal injuries or improve sleep. FDA has not approved it and identifies compounded GHRP-6 as presenting safety concerns, including possible peptide impurities, immune reactions and effects on cortisol and glucose regulation.

What exactly is GHRP-6?

The name describes both the intended effect and the size of the molecule. GHRP means growth hormone-releasing peptide. The number 6 refers to a hexapeptide, a chain of six residues. A residue is what an amino acid is called after it has been joined into a peptide chain.

The commonly reported sequence is His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. Written out, that is histidine, D-tryptophan, alanine, tryptophan, D-phenylalanine and lysine, followed by an amidated end. Amidation replaces the ordinary acidic end of the chain with an amide group and can change stability and biological activity.

Two residues use the D orientation. D-amino acids are mirror-image forms of the L-amino acids normally used to build human proteins. Their presence can make a designed peptide more resistant to enzymes that would otherwise cut it apart. GHRP-6 is therefore not a fragment removed from human growth hormone, and the body does not naturally make this exact sequence.

SKF-110679 is an earlier development code associated with GHRP-6. The name may appear with or without a hyphen, as GHRP6 or GHRP-6. These labels can identify the active sequence, but they do not prove that two finished products have the same salt, purity, sterility, stability or impurity profile.

Is GHRP-6 growth hormone, GHRH or a steroid?

No. GHRP-6 is a signal that can prompt growth hormone release. It is not growth hormone itself.

Growth hormone is a protein containing 191 amino acids. It is stored and released by the pituitary gland, a small hormone-producing organ at the base of the brain. GHRP-6 is a much smaller synthetic molecule that acts mainly through the growth hormone secretagogue receptor, now commonly called the ghrelin receptor.

Growth hormone-releasing hormone, shortened to GHRH, is a natural 44-amino-acid hormone made by the hypothalamus, a hormone-controlling region of the brain. GHRH activates the GHRH receptor. GHRP-6 activates a different receptor. Experiments found that the two signals can reinforce one another, which helped researchers understand that they use related but separate routes.

GHRP-6 is also not an anabolic steroid. Anabolic steroids are testosterone-related compounds that act through androgen receptors. GHRP-6 has a different chemical structure and target. Being non-steroidal does not make it safe, approved or effective for physique or performance goals.

How does the normal growth hormone system work?

Growth hormone is released in pulses rather than at a constant rate. The hypothalamus helps control those pulses through two main signals. GHRH encourages release, while somatostatin restrains it. Somatostatin is a natural hormone that reduces the release of several other hormones.

Specialised pituitary cells called somatotrophs store growth hormone. When the balance of signals favours release, growth hormone enters the bloodstream. It can act directly on tissues and can prompt the liver and other tissues to make insulin-like growth factor 1, normally shortened to IGF-1. IGF-1 supports normal growth and tissue maintenance and also feeds information back to the brain and pituitary.

Age, sleep, nutritional state, body fat, exercise, sex hormones and illness all influence this system. A large growth hormone response during one carefully controlled laboratory test does not show that repeated exposure will produce the same response or improve a person's health.

Ghrelin is another part of the system. It is a natural hormone made mainly in the stomach. Its active acylated form carries a fatty-acid group that allows it to activate the ghrelin receptor. Ghrelin can influence appetite, stomach movement, glucose regulation and growth hormone release.

GHRP-6 activates the same receptor without copying ghrelin's structure. An agonist is a molecule that switches a receptor on. Because the ghrelin receptor is found in the pituitary, brain and other tissues, activating it can affect more than one hormone or organ system.

What is GHRP-6 made from?

GHRP-6 is assembled from six amino-acid derivatives:

  • L-histidine at the first position.
  • D-tryptophan at the second position.
  • L-alanine at the third position.
  • L-tryptophan at the fourth position.
  • D-phenylalanine at the fifth position.
  • L-lysine at the sixth position.
  • An amide group at the end of the chain.

Histidine, alanine, tryptophan, phenylalanine and lysine are amino acids found in human proteins. The D forms are artificial mirror-image versions in this context. The arrangement matters. A material with the same total mass but the wrong orientation at one position may behave differently.

Chemical databases report the formula C46H56N12O6 for the uncharged peptide and a molecular weight of about 873 daltons. A dalton is a unit used for the mass of atoms and molecules. A finished research material may instead be supplied as an acetate or another salt, which changes the total measured mass and may influence solubility.

The peptide is made from chemical raw materials rather than extracted from human growth hormone, pituitary tissue or stomach tissue.

How is GHRP-6 synthesised and manufactured?

GHRP-6 can be produced by solid-phase peptide synthesis. This method builds a peptide while one end is attached to an insoluble resin bead. The manufacturer adds protected amino-acid derivatives in the required sequence.

Temporary protective groups stop the wrong parts of an amino acid reacting during each cycle. A cycle usually removes one protective group, activates the next building block and forms a peptide bond. Coupling reagents help create that bond. Solvents wash away unused material and reaction by-products before the next residue is added.

The raw materials include protected histidine, D-tryptophan, alanine, tryptophan, D-phenylalanine and lysine, as well as resin, coupling reagents, bases, solvents and reagents used to form the terminal amide. These materials need defined identity and quality because errors can carry into the final peptide.

After chain assembly, strong chemical reagents release the peptide from the resin and remove most remaining protective groups. This produces a crude mixture rather than a finished medicine. The mixture can contain the intended chain, shorter deletion sequences, incompletely deprotected material, oxidised tryptophan products, residues joined in the wrong orientation and chemicals left from manufacture.

Preparative high-performance liquid chromatography, shortened to HPLC, can separate the main peptide from many impurities. Analytical HPLC estimates how much of each separated component is present. Mass spectrometry measures mass-to-charge patterns and can support confirmation of the expected molecular mass. Neither method alone proves every aspect of identity.

Manufacturers may also use amino-acid analysis, peptide mapping or nuclear magnetic resonance methods. Nuclear magnetic resonance examines how atomic nuclei behave in a magnetic field and can provide structural information. Confirming D and L orientation may require a method designed for stereochemistry, which is the three-dimensional arrangement of atoms.

The purified peptide may be converted to a salt and freeze-dried. Freeze-drying removes water under low temperature and reduced pressure. It does not make a material sterile or remove endotoxins. Endotoxins are inflammatory bacterial components that can remain after living bacteria have been removed.

For a product intended for injection, manufacture also requires validated sterility, endotoxin and particle controls, along with evidence that the container and storage conditions preserve the material. Aggregation must be assessed. An aggregate is a cluster of peptide molecules, and aggregates can change activity or increase the chance of an unwanted immune response.

FDA specifically identifies aggregation, peptide-related impurities and limited characterisation as concerns for compounded GHRP-6. A certificate stating a high percentage purity does not by itself establish sequence, sterility, endotoxin control, dose accuracy, stability or clinical suitability.

When was GHRP-6 first documented?

The story began with modified enkephalins. Enkephalins are natural peptides involved in opioid signalling. Researchers found that changing these short chains could produce growth hormone release without relying on ordinary opioid activity.

In 1981, Momany and colleagues described the design and synthesis of peptides with growth hormone-releasing activity. They worked through chemical changes to identify the parts of the sequence linked with that effect.

In 1984, Bowers and colleagues reported a six-residue compound written at the time as His-D-Trp-Ala-Trp-D-Phe-Lys-NH2. This became known as GHRP-6. The paper examined pituitary cells and several animal species, including rats, monkeys, lambs and calves. It showed growth hormone release but did not establish a human treatment.

During the following decade, small human experiments used GHRP-6 to investigate how growth hormone release was controlled. In 1995, researchers reported effects on overnight growth hormone, stress hormones and sleep measurements in healthy men.

Scientists cloned the growth hormone secretagogue receptor in 1996. In 1999, they identified ghrelin from the stomach as the receptor's natural hormone. This reversed the usual order of discovery: the synthetic tools and receptor came before the natural signal.

Researchers later examined GHRP-6 in endocrine testing and measured its movement through the body. A separate programme combined GHRP-6 with epidermal growth factor after acute ischaemic stroke. A small Phase I/II study was published in 2024, followed by the 188-person Phase III COURAGE-2 report in 2026.

YearDevelopment
1981Researchers described the design and synthesis of early growth hormone-releasing peptides
1984The six-residue sequence later called GHRP-6 was reported in pituitary-cell and animal experiments
Early 1990sHuman endocrine studies mapped interactions with GHRH, somatostatin and glucose-lowering tests
1995A controlled overnight study examined growth hormone, ACTH, cortisol and sleep measurements
1996Scientists cloned the growth hormone secretagogue receptor
1999Ghrelin was identified as the receptor's natural hormone
2000sStudies examined GHRP-6 in diagnostic testing for growth hormone deficiency
2013A nine-person study reported human pharmacokinetic measurements
2024A 36-person Phase I/II trial tested GHRP-6 with epidermal growth factor after ischaemic stroke
2026COURAGE-2 reported no overall disability benefit from the combination in 188 stroke patients

How does GHRP-6 work?

GHRP-6 binds to the active form of the ghrelin receptor, usually written as GHS-R1a. The receptor belongs to a family of proteins that cross the cell membrane and pass a signal inside when activated.

On pituitary somatotrophs, receptor activation raises calcium inside the cell. Calcium is one of the signals that allows stored growth hormone to be released. GHRP-6 also acts through the hypothalamus, where it interacts with natural GHRH and somatostatin control.

Human experiments showed that GHRP-6 and GHRH can produce a much larger response together than either produces alone. Researchers call this synergy. It helped show that the two compounds do not act through the same receptor. It does not show that combining them is a useful or safe treatment.

The response can be changed by other signals. In a 1993 study, atropine almost completely prevented the growth hormone response to GHRP-6. Atropine blocks certain acetylcholine signals. Pyridostigmine, which increases acetylcholine activity, slightly increased the response. These experiments helped researchers examine the role of somatostatin control.

The ghrelin receptor also connects with appetite-regulating nerve cells, glucose control, stomach movement and stress-hormone pathways. This wider receptor biology is why GHRP-6 cannot be treated as a perfectly selective switch for growth hormone.

What do we know about its duration in the body?

A 2013 pharmacokinetic study enrolled nine healthy men. Pharmacokinetics describes what the body does to a compound through distribution, breakdown and removal. Participants received one of three intravenous research levels: 100, 200 or 400 micrograms per kilogram of body weight.

The study reported a rapid distribution phase with an average half-life of 7.6 minutes and a later elimination half-life averaging 2.5 hours. Distribution is the early movement of material from blood into tissues. Elimination is the later process by which the measured material leaves the body. A half-life is the time required for the measured amount to fall by half.

The highest measured concentration increased with the administered level. Total exposure also increased, although the small number of participants makes precise conclusions difficult. The investigators reported no moderate or serious adverse events in this nine-person study.

These values apply to the defined intravenous material and methods used in that experiment. They do not establish the same profile for a subcutaneous, intranasal, oral, compounded or unverified product. They also do not show how long every biological effect lasts.

Urine detection research found that GHRP-6 was mainly identified as unchanged peptide rather than through a dominant metabolite. A detection window is useful for laboratory testing but is not the same as an active duration or a safe interval.

What human research exists?

The human evidence falls into four main groups:

  1. Small physiology studies measuring growth hormone and other hormone responses.
  2. Diagnostic studies asking whether GHRP-6 could help identify growth hormone deficiency.
  3. A nine-person study measuring pharmacokinetics and short-term tolerability.
  4. Stroke trials testing GHRP-6 only as part of a combination with epidermal growth factor.

This record shows biological activity in people. It does not establish a general treatment. Most early studies used hormone concentrations as their main outcomes. A biomarker is a measurable biological sign, such as a hormone level. A biomarker change can help explain mechanism without showing that a person feels better, functions better or lives longer.

No controlled clinical programme has established GHRP-6 for muscle gain, fat loss, injury healing, anti-ageing, sleep improvement or appetite treatment. The stroke programme cannot answer those questions and cannot separate the contribution of GHRP-6 from epidermal growth factor.

What did the early hormone studies find?

Early human studies used GHRP-6 as a tool to understand growth hormone control. They often compared it with GHRH or changed another part of the hormone system before measuring the response.

In one 1993 experiment, healthy participants received GHRP-6, GHRH or both. The growth hormone response to either compound alone was similar, while the combined response was several times larger. Additional study visits used atropine, pyridostigmine or insulin-induced hypoglycaemia. Hypoglycaemia means abnormally low blood glucose. These conditions altered the response and helped researchers examine the role of the hypothalamus and somatostatin.

A 1998 study used a GHRH receptor antagonist before GHRP-6. An antagonist blocks a receptor. Reducing natural GHRH signalling weakened the maximum GHRP-6 response, supporting the view that natural GHRH contributes to the full effect.

These experiments were designed to answer physiological questions. They do not show that repeated GHRP-6 produces stable benefits, and their close monitoring cannot be compared with unsupervised exposure.

Has GHRP-6 been used in diagnostic research?

Yes. A provocative test gives a substance once to challenge a hormone system and measures the response. Researchers studied GHRP-6 alone and with GHRH as possible tests of growth hormone reserve.

Growth hormone deficiency can be difficult to diagnose because the hormone is released in pulses. A random blood measurement may therefore be low in a healthy person. Provocative tests attempt to create a measurable response under standard conditions.

The insulin tolerance test has often been used as a reference test. It deliberately lowers blood glucose under medical supervision and measures growth hormone and cortisol responses. Because severe hypoglycaemia can be dangerous, researchers have examined alternatives.

Multicentre work compared combined GHRH and GHRP-6 testing with the insulin tolerance test. Multicentre means that more than one clinical centre took part. Other researchers studied GHRP-6 alone or in combinations. Results suggested that these compounds could provoke a measurable response, but thresholds depended on the test, laboratory method and patient group.

This diagnostic research does not make GHRP-6 an approved treatment. A one-time challenge test and repeated therapeutic exposure ask different questions and carry different risks.

What did the sleep study show?

A 1995 controlled experiment compared four 50-microgram intravenous GHRP-6 administrations with placebo during the night in healthy men. A placebo is an inactive comparison intended to separate the effect of the tested substance from time, expectation and the study procedure.

Researchers recorded an electroencephalogram, shortened to EEG. An EEG measures patterns of electrical activity at the scalp and is used to classify sleep stages. They also measured growth hormone, adrenocorticotropic hormone and cortisol. Adrenocorticotropic hormone, normally shortened to ACTH, is a pituitary signal that prompts the adrenal glands to release cortisol. Cortisol is involved in the stress response, metabolism and immune regulation.

Average growth hormone concentrations during part of the night were 15.4 nanograms per millilitre after GHRP-6 and 5.5 after placebo. ACTH and cortisol also increased. Stage 2 sleep lasted about 270 minutes after GHRP-6 and 245 minutes after placebo, while slow-wave sleep did not significantly increase.

Stage 2 is a lighter non-rapid-eye-movement sleep stage. Slow-wave sleep is the deeper stage often discussed in relation to physical restoration. The finding was therefore not a simple improvement in sleep quality. The study was small, used repeated intravenous exposure in a laboratory and measured a single night.

It does not establish GHRP-6 as a treatment for insomnia or poor sleep. Increasing ACTH and cortisol at night may also be undesirable, depending on the person and context.

Does GHRP-6 increase appetite?

GHRP-6 is widely described online as a powerful hunger peptide. Its receptor makes that claim biologically plausible, but the direct human evidence is often overstated.

Ghrelin can increase hunger, and the ghrelin receptor is involved in feeding behaviour. Animal experiments with GHRP compounds also support an appetite effect. However, the clearest controlled human feeding studies located for this peptide family used GHRP-2, not GHRP-6.

In those GHRP-2 studies, researchers measured food eaten from a buffet after controlled exposure. It is not sound to transfer the numerical result from one compound to another simply because both activate the ghrelin receptor. Differences in receptor activity, route, exposure and additional hormone effects may matter.

Some participants in GHRP-6 research may have reported hunger, and mechanistic reviews discuss appetite. That is weaker than a controlled study designed to measure food intake. The current evidence supports saying that increased hunger is possible, not that a precise appetite effect has been proven for a particular GHRP-6 product or exposure pattern.

Does GHRP-6 build muscle or reduce body fat?

There is no good clinical evidence that GHRP-6 produces useful muscle gain, greater strength or reliable fat loss.

Growth hormone and IGF-1 are involved in body composition, which makes the claim sound reasonable. That is not enough. A short rise in a hormone is a surrogate outcome, meaning an indirect measurement used in place of an outcome that matters to a person.

A convincing muscle study would need a defined GHRP-6 product, an appropriate comparison group, random allocation, enough participants and validated measurements of lean tissue, strength and physical function. Random allocation means assigning participants by chance to reduce systematic differences between groups. It would also need adequate follow-up and safety monitoring.

A convincing fat-loss study would need to measure body fat with a validated method and show that any change is clinically meaningful and sustainable. It would need to separate a drug effect from food intake, activity and loss of water or lean tissue.

The available human GHRP-6 studies were not designed to do this. Animal findings or hormone responses cannot fill the gap.

Does GHRP-6 help injuries heal?

No controlled human trial has established GHRP-6 for tendon, ligament, muscle or bone healing.

Laboratory and animal papers have examined GHRP-6 in cardiac injury, kidney injury and other experimental models. These studies may identify biological pathways worth investigating. They do not reproduce a human sports injury or show safe recovery of function.

For example, rat studies have reported effects after experimental heart attack or kidney injury. A rat model deliberately creates a particular form of tissue damage under controlled conditions. Species differences, artificial timing, the method used to create injury and the measured outcomes all limit transfer to people.

Evidence for a human healing treatment would require trials measuring pain, tissue integrity, physical function, return to activity and re-injury. Those data are not available for GHRP-6.

Why was GHRP-6 studied after ischaemic stroke?

An ischaemic stroke occurs when a blood vessel supplying part of the brain is blocked. Brain tissue can be injured because it does not receive enough oxygen and glucose. Standard urgent treatments aim to restore blood flow when appropriate and prevent further harm.

Researchers in Cuba developed an experimental combination of GHRP-6 and epidermal growth factor. Epidermal growth factor, shortened to EGF, is a protein signal involved in cell growth and repair. Preclinical studies suggested that the combination might affect cell survival and tissue responses after injury.

The treatment was not based simply on releasing growth hormone. It was a two-compound biological programme. Any result must therefore be attributed to the combination unless a study compares the components separately.

The clinical programme examined people with acute ischaemic stroke, meaning treatment began soon after symptoms rather than months later during rehabilitation. It did not study chronic injuries, bodybuilding recovery or general brain enhancement.

What did the Phase I/II stroke trial find?

A 2024 report described a randomised, open-label Phase I/II trial in 36 adults with acute ischaemic stroke. Randomised means participants were assigned by chance. Open-label means participants and clinicians knew which treatment was given. Phase I/II combines an early safety question with an initial look at possible activity.

Sixteen participants received standard care. Ten received standard care plus a lower-level combination containing 75 micrograms of EGF and 3.5 milligrams of GHRP-6. Another ten received standard care plus 75 micrograms of EGF and 5 milligrams of GHRP-6. The experimental combination was given intravenously twice daily for seven days.

These quantities describe the trial and are not recommendations. The study took place in hospital after an acute medical emergency.

Serious adverse events occurred in nine of 16 standard-care participants, three of ten in the lower-level group and two of ten in the higher-level group. A serious adverse event is an event that meets criteria such as death, threat to life, hospital admission or important disability. Only two events in one participant were judged related to the experimental treatment.

The sample was too small to establish effectiveness or detect uncommon harms. Open-label assessment also creates a risk of bias, particularly for outcomes influenced by care or judgement. The results supported a larger trial, not routine treatment.

What did the 2026 COURAGE-2 trial find?

COURAGE-2 was a Phase III, randomised, open-label trial. Phase III normally means a larger study intended to provide stronger evidence about whether a treatment works and how safe it is. The full name refers to the research group's combined therapeutic approach during acute stroke.

The trial enrolled 188 adults with acute ischaemic stroke within 12 hours of symptom onset. Their National Institutes of Health Stroke Scale scores were between 5 and 20. This scale, shortened to NIHSS, grades neurological impairment such as weakness, language difficulty and reduced awareness. Higher scores generally indicate a more severe stroke.

Ninety-five participants received standard care plus 75 micrograms of EGF and 5 milligrams of GHRP-6 intravenously twice daily for seven days. Ninety-three received standard care alone. These are documented trial levels, not administration guidance.

The main outcome used the modified Rankin Scale at three and six months. The modified Rankin Scale, shortened to mRS, grades disability from no symptoms to death. The study was designed to show at least 20% greater improvement with the combination.

The trial did not meet that main target. In the intention-to-treat analysis, the full groups did not differ significantly in mRS disability, Barthel Index or survival. Intention-to-treat means analysing people according to the group to which they were originally assigned, which helps preserve the benefits of randomisation. The Barthel Index measures independence in everyday activities such as feeding, washing and moving.

Serious adverse events occurred in 30 of 95 people in the combination group and 18 of 93 in the standard-care group. The estimated odds ratio was 1.92, with a 95% confidence interval from 0.981 to 3.767. An odds ratio above 1 suggests more events in the treatment group. A confidence interval shows the range of values reasonably compatible with the data. Because this interval crossed 1, the difference did not meet the usual threshold for statistical significance. Investigators did not judge the serious events treatment-related, but the numerical imbalance still belongs in the safety picture.

Researchers also reported a better disability score and lower mortality in an exploratory subgroup of 27 people with NIHSS scores of at least 15. Exploratory means the analysis can generate a hypothesis but is not as reliable as the trial's planned main result. A small subgroup is more vulnerable to chance findings. The negative result in the full study population remains the central finding.

COURAGE-2 therefore does not establish the EGF and GHRP-6 combination as an effective stroke treatment. It also cannot show whether GHRP-6 alone helped, harmed or had no effect.

What have cell and animal studies found?

Cell and animal studies have examined growth hormone release, heart injury, kidney injury, inflammation and the EGF combination. They are useful for studying mechanisms and deciding whether human research is justified.

The original 1984 work tested pituitary tissue and several animal species. It established that the sequence could release growth hormone across experimental systems. It did not examine long-term human outcomes.

In rat heart-attack models, researchers reported changes in heart injury and function. Other teams studied the EGF and GHRP-6 combination in rat kidney injury. More recent work has continued to examine cardiac remodelling and experimental delivery systems.

Remodelling means changes in the size, shape and structure of an organ after injury. A delivery system such as a hydrogel is a water-rich material designed to hold and release a compound. These are research concepts, not evidence that ordinary GHRP-6 products reproduce the same exposure.

Animal studies can control timing, genetics and injury severity in ways that are impossible in clinical life. Results can also depend on species, dose scaling and laboratory methods. Positive animal findings should be described as preclinical evidence, not human benefit.

What are the known safety concerns?

GHRP-6 does not have the large, long-term safety record expected of an approved medicine. The main concerns come from receptor biology, small human studies, the stroke programme, regulatory review and uncertainty about compounded or research-market products.

Growth hormone and IGF-1 effects

Repeated or excessive activation of the growth hormone system could affect fluid balance, joints, nerves and glucose regulation. The actual risk from GHRP-6 cannot be quantified well because long-term controlled trials are lacking.

ACTH and cortisol

The overnight study found increases in ACTH and cortisol. These are not minor laboratory details. Cortisol influences glucose, blood pressure, sleep and immune function. A short study cannot show what repeated changes would mean.

Glucose and insulin sensitivity

FDA highlights concern that GHRP-6 may raise blood glucose by reducing insulin sensitivity. Insulin sensitivity describes how effectively the body's cells respond to insulin and take glucose from the blood. People with diabetes or impaired glucose regulation could be particularly vulnerable, but adequate clinical safety studies have not defined the risk.

Appetite and food intake

Increased hunger is plausible through the ghrelin receptor. It could be unwanted for some people or alter glucose and weight control. Direct human feeding evidence for GHRP-6 is limited, so the size and consistency of the effect are uncertain.

Immune and manufacturing risk

Peptide impurities or aggregates may provoke an immune response. Injection adds risks from sterility failures, endotoxins and particles. These risks concern the finished product, not only the active sequence.

Unknown long-term effects

There is not enough evidence to define long-term effects on the pituitary, metabolism, cardiovascular system, tumour biology or immune system. Absence of a reported event in a nine-person study is not evidence that the event cannot occur.

What does FDA say about GHRP-6?

FDA has not approved GHRP-6 as a medicine. Compounded drugs are not FDA approved, which means the agency does not verify their safety, effectiveness or quality before marketing in the way it does for an approved product.

FDA lists GHRP-6 among bulk substances for which compounded products may present significant safety risks. The agency points to aggregation, peptide-related impurities and limited safety information. It also notes possible effects on cortisol and blood glucose caused by reduced insulin sensitivity.

In the May 2026 503A bulk-substances categories, GHRP-6 appears in category 3. Category 3 means it was nominated for use in compounding without adequate support for evaluation. It is not an approval category.

Section 503A concerns certain patient-specific compounding by pharmacies or physicians. Section 503B concerns outsourcing facilities operating under a different federal framework. Neither route turns an unapproved peptide into an FDA-approved medicine.

Is GHRP-6 prohibited in sport?

Yes. The World Anti-Doping Agency, commonly called WADA, names GHRP-6 among growth hormone-releasing factors prohibited at all times. For athletes covered by the World Anti-Doping Code, at all times means both in and out of competition.

Laboratories can detect GHRP-6 in urine with mass-spectrometry methods. Research indicates that unchanged GHRP-6 is an important target for detection. Analytical detectability does not tell a person whether a product is safe, effective or accurately labelled.

Rules and therapeutic-use-exemption requirements can change. An athlete remains responsible for substances found in their sample and should use current official anti-doping information.

What product-quality questions matter?

The name GHRP-6 does not answer whether a product contains the correct molecule or is suitable for human administration. A meaningful quality assessment would ask:

  • Is the sequence His-D-Trp-Ala-Trp-D-Phe-Lys-NH2?
  • Are the two D-amino acids in the correct positions and orientation?
  • Is the C-terminal amide present?
  • Which salt or counterion is present?
  • Are deletion sequences, oxidised tryptophan products and aggregates controlled?
  • Does the container contain the stated amount?
  • Has stability been studied under the stated conditions?
  • For an injectable product, have sterility, endotoxin and particle controls been validated?

A headline HPLC purity percentage cannot answer all of these questions. It may estimate the area of the main separated peak without proving sequence, stereochemistry, quantity, biological activity or sterility.

A research-use-only label does not create a separate biological category. If a material is put into a person, its identity, impurities, microorganisms, endotoxins and particles can all matter.

How does GHRP-6 compare with GHRP-2?

Both are six-residue synthetic agonists of the ghrelin receptor. They are related but not interchangeable.

FeatureGHRP-6GHRP-2
Common sequenceHis-D-Trp-Ala-Trp-D-Phe-Lys-NH2D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH2
Human growth hormone evidenceMany small endocrine-provocation studiesEndocrine studies plus validated Japanese diagnostic use
Direct controlled human feeding evidenceLimited evidence locatedTwo controlled studies measured increased food intake
Longer clinical programmeEGF combination in acute stroke, with a negative overall Phase III resultRepeated endocrine, paediatric and critical-illness studies
Regulatory positionNot FDA approvedDiagnostic medicine in Japan, but not FDA approved

Online descriptions often label GHRP-6 as the hunger compound and GHRP-2 as the stronger growth hormone compound. The first claim is commonly repeated without the direct human feeding evidence needed to quantify it. GHRP-2 has clearer controlled human food-intake data.

The Japanese pralmorelin test belongs to GHRP-2, not GHRP-6. The COURAGE stroke programme belongs to a GHRP-6 and EGF combination, not GHRP-2. Evidence should stay attached to the compound and formulation that were actually studied.

How does GHRP-6 compare with other growth hormone secretagogues?

CompoundMain routeStrongest human evidenceApproval position
GHRP-6Ghrelin receptorSmall endocrine studies, pharmacokinetics and an EGF combination in stroke trialsUnapproved in the US
GHRP-2 / pralmorelinGhrelin receptorJapanese diagnostic validation and controlled appetite studiesJapanese diagnostic medicine; not FDA approved
IpamorelinGhrelin receptorEarly pharmacology and unsuccessful postoperative bowel-recovery developmentUnapproved
HexarelinGhrelin receptorSmall endocrine and cardiac physiology studiesUnapproved
SermorelinGHRH receptorOlder diagnostic and paediatric research on GHRH(1-29)Former US diagnostic medicine; current compounded products are not approved
TesamorelinGHRH receptorControlled clinical trials in adults with HIV-associated lipodystrophyUsed in approved EGRIFTA products for a specific indication

Receptor route is not the same as evidence quality. Tesamorelin's approved use comes from defined products and condition-specific trials. It does not validate GHRP-6 or a combination of the two.

What claims are not established?

Current evidence does not establish GHRP-6 for:

  • Building useful muscle or increasing strength.
  • Reducing body fat or producing lasting weight loss.
  • Healing tendon, ligament, muscle or bone injuries.
  • Improving sleep quality or treating insomnia.
  • Reversing ageing or improving general wellbeing.
  • Treating growth hormone deficiency outside approved specialist pathways.
  • Protecting the heart, kidneys or brain in routine clinical care.
  • Treating stroke alone or in an approved EGF combination.
  • Providing a safer alternative to prescribed growth hormone.

Some claims begin with a genuine laboratory observation. The error is moving from receptor activation or a hormone increase to a clinical promise without the necessary trials.

What would stronger evidence require?

The first step would be a precisely defined product. Researchers would need to establish sequence, D and L orientation, salt form, impurities, aggregation, stability and, where relevant, sterility and endotoxin control.

An early repeated-exposure study would need to measure GHRP-6 concentration, growth hormone, IGF-1, ACTH, cortisol, glucose and insulin across time. It would also need to examine whether the response weakens, whether antibodies develop and how long changes last after exposure ends.

A treatment trial would need one clearly defined medical condition and an outcome meaningful to patients. A muscle trial would need strength and function, not growth hormone alone. A sleep trial would need validated sleep and daytime-function outcomes over more than one night. An injury trial would need healing, pain, return to activity and re-injury measures.

Trials should use random allocation, a suitable placebo or active comparison, masking where possible and enough participants to detect useful effects and important harms. Masking means keeping participants, researchers or outcome assessors unaware of group assignment to reduce bias.

The stroke programme would need independent confirmation and a design capable of separating the effects of EGF and GHRP-6. A positive result in a small exploratory subgroup would need to be tested as a planned question in a new trial.

Longer follow-up would be required for glucose control, pituitary effects, cardiovascular outcomes, immune reactions and any concern about stimulating unwanted tissue growth.

FREQUENTLY ASKED QUESTIONS

Frequently asked questions

What does GHRP-6 stand for?

It stands for growth hormone-releasing peptide 6. The number refers to its six linked amino-acid-like residues.

Is GHRP-6 growth hormone?

No. It activates the ghrelin receptor and can prompt the pituitary to release growth hormone. Growth hormone is a different 191-amino-acid protein.

Is GHRP-6 the same as ghrelin?

No. Ghrelin is a natural hormone made mainly in the stomach. GHRP-6 is a synthetic six-residue agonist that activates the ghrelin receptor despite having a different structure.

Is GHRP-6 approved as a medicine?

FDA has not approved it. The human research record does not establish it as a general treatment for growth hormone deficiency, physique, recovery, sleep or appetite.

Does GHRP-6 increase growth hormone?

Yes, controlled human studies show an acute growth hormone response. A hormone rise is a biomarker finding and does not prove muscle gain, fat loss, healing or improved health.

Does GHRP-6 make people hungry?

Increased hunger is biologically plausible, but direct controlled human food-intake evidence is limited. The strongest numerical feeding studies commonly used to support the claim tested GHRP-2, not GHRP-6.

Does GHRP-6 improve sleep?

One small overnight study found more stage 2 sleep but no significant increase in deep slow-wave sleep. It also increased ACTH and cortisol. This does not establish a treatment for poor sleep.

What did the stroke trials test?

They tested GHRP-6 together with epidermal growth factor after acute ischaemic stroke. They did not test GHRP-6 alone. The 2026 Phase III trial did not improve the main disability outcome in the full study population.

Was the severe-stroke subgroup positive?

An exploratory subgroup of 27 people with more severe strokes had better reported disability and mortality results. The subgroup was small and the trial's main result was negative, so the finding needs confirmation in a new planned trial.

Does GHRP-6 build muscle or reduce fat?

No controlled clinical trial has established useful muscle gain, strength improvement or fat loss. Short hormone changes cannot substitute for those outcomes.

Is GHRP-6 the same as GHRP-2?

No. Both activate the ghrelin receptor, but their sequences and evidence records differ. GHRP-2 has a Japanese diagnostic use and clearer controlled human appetite evidence.

What is the half-life of GHRP-6?

A nine-person intravenous study reported a rapid distribution half-life averaging 7.6 minutes and a later elimination half-life averaging 2.5 hours. Those values should not be transferred to every route or product.

Are the administration levels in this guide recommendations?

No. They document published experiments so that the evidence can be understood. They are not personal dosing, preparation or administration advice.

Is compounded GHRP-6 FDA approved?

No. Compounded drugs are not FDA approved. FDA identifies compounded GHRP-6 as presenting concerns related to impurities, aggregation, immune reactions, cortisol and glucose regulation.

Is GHRP-6 prohibited in sport?

Yes. WADA names GHRP-6 among substances prohibited at all times for athletes covered by its rules.

RESEARCH AND MEDICAL NOTICE

This guide explains published research and its limits. It does not recommend GHRP-6, provide a dose, describe preparation or administration, propose a cycle or advise combining it with another compound. The administration levels reported above belong only to the cited studies.

RESEARCH LIBRARY

Sources

Regulatory and anti-doping sourcesFDA
FDA: compounded bulk substances that may present significant safety risksOpen source →
Regulatory and anti-doping sourcesFDA
FDA: May 2026 503A bulk-substances categoriesOpen source →
Regulatory and anti-doping sourcesWorld Anti-Doping Agency
World Anti-Doping Agency: 2026 Prohibited ListOpen source →
Chemistry, discovery and mechanismpubchem.ncbi.nlm.nih.gov
PubChem: GHRP-6Open source →
Chemistry, discovery and mechanismPubMed
Momany and colleagues: design and synthesis of early growth hormone-releasing peptidesOpen source →
Chemistry, discovery and mechanismPubMed
Bowers and colleagues: 1984 GHRP-6 development paperOpen source →
Chemistry, discovery and mechanismPubMed
Bowers: growth hormone-releasing peptide reviewOpen source →
Chemistry, discovery and mechanismPubMed
Growth hormone-releasing peptides and their analoguesOpen source →
Chemistry, discovery and mechanismPubMed
History of ghrelin and its receptor systemOpen source →
Chemistry, discovery and mechanismPubMed
GHRP-6 response after GHRH, atropine, pyridostigmine or hypoglycaemiaOpen source →
Chemistry, discovery and mechanismPubMed
Natural GHRH contribution to the GHRP-6 responseOpen source →
Human endocrine, sleep and pharmacokinetic evidencePubMed
GHRP-6, overnight hormones and sleepOpen source →
Human endocrine, sleep and pharmacokinetic evidencePubMed
Pharmacokinetics in nine healthy menOpen source →
Human endocrine, sleep and pharmacokinetic evidencePubMed
Multicentre comparison of GHRH plus GHRP-6 and the insulin tolerance testOpen source →
Human endocrine, sleep and pharmacokinetic evidencePubMed
GHRP-6 alone and combined testing in growth hormone deficiencyOpen source →
Human endocrine, sleep and pharmacokinetic evidencePubMed
Reference values for growth hormone deficiency testsOpen source →
Appetite contextPubMed
Review of ghrelin's multiple functionsOpen source →
Appetite contextPubMed
Controlled GHRP-2 food-intake study in healthy menOpen source →
Appetite contextPubMed
Controlled GHRP-2 food-intake study in lean and obese adultsOpen source →
Stroke researchPubMed
Phase I/II EGF and GHRP-6 trial in acute ischaemic strokeOpen source →
Stroke researchPubMed
COURAGE-2 Phase III trialOpen source →
Preclinical researchPubMed
GHRP-6 in a rat myocardial-infarction modelOpen source →
Preclinical researchPubMed
EGF and GHRP-6 in a rat kidney-injury modelOpen source →
Preclinical researchPubMed
GHRP-6 in experimental doxorubicin injury modelsOpen source →
Preclinical researchPubMed
GHRP-6 and post-infarct ventricular remodelling in ratsOpen source →
Analytical researchPubMed
Metabolism and detection windows of growth hormone-releasing peptidesOpen source →
Analytical researchPubMed
Detection of GHRP-2 and GHRP-6 in athlete samplesOpen source →

Research reviewed through September 2026.